MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.

Consuelo PitolliAlberto MariniMarika GuerraMarco PieraccioliVeronica MarabittiFernando PalluzziLuciano GiacòGianpiero TamburriniFrancesco CecconiFrancesca NazioClaudio SetteVittoria Pagliarini

Published in: Journal of experimental & clinical cancer research : CR (2023)

Our study demonstrates that CDK12/13 activity represents an exploitable vulnerability in MYC-high Group 3 MB and may pave the ground for new therapeutic approaches for this high-risk brain tumor.

Keyphrases

cell cycle
climate change
transcription factor
cell proliferation